

Up-and-Down Determination of Different Crystalloid Coload Volumes on the ED 90 of Prophylactic Norepinephrine Infusion for Preventing Postspinal Anesthesia Hypotension During Cesarean Section

Yi Chen^{1,*}, Xiangsheng Xiong^{2,*}, Rui Qin¹, Lei Guo¹, Yongqiang Shi¹, Xinli Ni¹

¹Department of Anesthesiology and Perioperative Medicine, General Hospital of Ningxia Medical University, Yinchuan, People's Republic of China;

²Department of Anesthesiology, the Fifth People's Hospital of Huaian, Huaian, People's Republic of China

*These authors contributed equally to this work

Correspondence: Xinli Ni, Department of Anesthesiology and Perioperative Medicine, General Hospital of Ningxia Medical University, Yinchuan, People's Republic of China, Email xinlini6@nyfy.com.cn

Background: Fluid loading improves hemodynamic stability and reduces the incidence rate of post-spinal anesthesia hypotension when prophylactic vasopressors are administered. We investigated the impact of different crystalloid coload volumes on the 90% effective dose (ED) of prophylactic norepinephrine infusion for preventing post-spinal anesthesia hypotension in non-hypertensive patients undergoing cesarean section.

Methods: Patients were randomly allocated to receive one of the different crystalloid coload volumes (0mL/kg [0mL/kg Group], 5mL/kg [5mL/kg Group], and 10mL/kg [10mL/kg Group]) in combination with prophylactic norepinephrine infusion immediately after the induction of spinal anesthesia. The prophylactic norepinephrine infusion doses were determined using the up-and-down sequential allocation methodology, with an initial dose of 0.025 µg/kg/min and a gradient of 0.005 µg/kg/min. The primary endpoint was the effective dose at which 90% (ED 90) of patients responded to prophylactic norepinephrine infusion for preventing post-spinal anesthesia hypotension.

Results: The estimated effective dose of norepinephrine infusion, at which 90% (ED 90) of patients responded, was found to be 0.084 (95% CI, 0.070 to 0.86), 0.074 (95% CI, 0.059 to 0.077), and 0.063 (95% CI, 0.053 to 0.064) µg/kg/min in the three groups, respectively.

Conclusion: A crystalloid coload of 5 mL/kg or 10 mL/kg, as opposed to the groups receiving 0 mL/kg crystalloid coloads, resulted in a reduction of approximately 11.9% and 25.0%, respectively, in the ED90 of prophylactic norepinephrine infusion for preventing post-spinal anesthesia hypotension during cesarean section.

Keywords: crystalloid, coload, norepinephrine, postspinal anesthesia hypotension, cesarean section

Introduction

As a common and high-frequency complication, post-spinal anesthesia hypotension during cesarean section warrants attention due to its contribution to a series of maternal and neonatal pathophysiological changes, including maternal organ hypoperfusion and fetal acidosis.^{1,2} Vasopressors are deemed as the foremost strategy to cope with post-spinal anesthesia hypotension during cesarean section, both in terms of prevention and treatment.³ Due to the extensive blockade of thoracolumbar sympathetic nerves and accompanying dilation of arteries in the lower limbs, vasopressors, particularly potent α -receptor agonists, can directly counteract dilated arteries as well as decreased peripheral vascular

resistance.⁴ This stabilizes both maternal blood pressure and cardiac output, while also preventing insufficient placental perfusion induced by maternal hypotension.⁵ Currently, norepinephrine is being considered as an alternative to phenylephrine for obstetric anesthesia due to its potent α -receptor agonist and weak β -receptor agonist properties, which help avoid bradycardia and maintain cardiac output.⁶

Fluid loading is recommended by an international consensus statement to improve hemodynamic stability and reduce the incidence rate of post-spinal anesthesia hypotension when prophylactic vasopressors are administered, in combination with the removal of inferior vena cava compression to optimize venous return in non-hypertensive parturients undergoing cesarean section.⁷ The optimal timing for fluid loading is crucial in maximizing these effects. Preloading (15–30 minutes prior to spinal anesthesia) was previously a common practice for cesarean section.⁸ However, it has been found that a crystalloid preload of 30mL/kg alone is insufficient in preventing post-spinal anesthesia hypotension.⁹ The practice has thus shifted towards coload, which involves the immediate administration of fluids loading following the induction of spinal anesthesia. Coload is a more effective approach to augment intravascular volume at the time of maximum arterial expansion (during the period of maximum arterial expansion) caused by sympathetic blockade.¹⁰

The administration of a 10 mL/kg crystalloid coload combined with prophylactic vasopressor infusion has been observed in several studies.^{11,12} It is still unknown whether the use of a relatively higher dose of crystalloid coload has an impact on the 90% effective dose (ED) of prophylactic norepinephrine infusion, and if a relatively smaller dose, such as 5 mL/kg, is inferior to a 10 mL/kg crystalloid coload. An up-and-down sequential allocation approach was employed to investigate the impact of different crystalloid coload volumes (0mL/kg, 5mL/kg, and 10mL/kg) on the ED 90 of prophylactic norepinephrine infusion for preventing post-spinal anesthesia hypotension in non-hypertensive patients undergoing cesarean section.

Methods

After obtaining approval from the Ethics Committees of General Hospital of Ningxia Medical University, Yinchuan, China (No. KYLL-2023-0118) on 27 February 2023 and The Fifth People's Hospital of Huaian, Huaian, China (No. 2023001) on 5 January 2023, as well as written informed consent from patients, this up-and-down sequential allocation study was conducted in compliance with the Declaration of Helsinki between March 2023 and June 2023 and registered at clinicaltrials.gov (NCT05690334).

Healthy ASA II patients (either primiparous or multiparous) with a singleton full-term pregnancy aged between 18 and 40 years, scheduled for an elective cesarean section under spinal anesthesia were included in this study. Patients having height less than 150 cm, body mass index (BMI) greater than 35 kg/m², coexisting chronic hypertension (baseline systolic blood pressure [SBP] greater than 160 mmHg) or pregnancy-induced hypertension, known abnormal fetal development and fetal distress were excluded in this study.

During the resting state in the operating room prior to spinal anesthesia, patients were positioned supine with left displacement of the uterus. Three consecutive readings of non-invasive SBP and heart rate (HR) were taken at 3-minute intervals to obtain the mean value, with a maximum difference of less than 10%, as baseline values. SBP and HR were measured at 1-minute intervals following induction of spinal anesthesia until fetal delivery, and subsequently at 5-minute intervals until the completion of the procedure. An 18-gauge intravenous (IV) catheter was inserted into the upper arm for norepinephrine (Batch No. 2301043, Jinyao Pharmaceutical, Tianjin, China) and crystalloid (Ringer's lactate) infusion. No pre-medication drugs and a crystalloid preload of 5 mL/kg were administered. Patients received a 12.5 mg (2.5 mL) dose of hyperbaric bupivacaine via a 25-gauge spinal needle at the estimated L3-4 vertebral interspace in the lateral decubitus position for spinal anesthesia, and subsequently positioned supine with left displacement of the uterus. After achieving a sensory blockade level of at least T6, as determined by loss of pinprick sensation with the use of a sterile needle, cesarean section was allowed to be performed.

The random sequences were enclosed within opaque containers. Immediately after the induction of spinal anesthesia, patients randomly received one of the different crystalloid coload volumes (0mL/kg [0mL/kg Group], 5mL/kg [5mL/kg Group], and 10mL/kg [10mL/kg Group]) over a period of 10–15 minutes using a pressure bag combined with prophylactic norepinephrine infusion based on a computer-generated randomization sequence. Patients and investigators involved in data recording and group assignment, rather than anesthesiologists involved in intraoperative patient

management, were blinded to the volumes of crystalloid coload. The crystalloid infusion rate was maintained at 6 mL/kg/h for fluid management up to a total volume of 2000 mL following fetal delivery until the completion of the procedure.

The prophylactic norepinephrine infusion doses were determined using the up-and-down sequential allocation methodology, with an initial dose of 0.025 $\mu\text{g}/\text{kg}/\text{min}$ and a gradient of 0.005 $\mu\text{g}/\text{kg}/\text{min}$. If the current dose did not show an efficacy in preventing post-spinal anesthesia hypotension, the norepinephrine gradient was increased by 0.005 $\mu\text{g}/\text{kg}/\text{min}$. If three consecutive doses showed efficacy, the norepinephrine gradient was decreased by 0.005 $\mu\text{g}/\text{kg}/\text{min}$.

The primary endpoint was the effective dose at which 90% (ED 90) of patients responded to prophylactic norepinephrine infusion for preventing post-spinal anesthesia hypotension. Secondary endpoints, including baseline values (SBP and HR), anesthetic and surgical characteristics (block height, consumption of norepinephrine, volume of coload, anesthesia - delivery interval, skin incision - delivery interval, and length of postoperative hospital stay), the incidence of post-spinal anesthesia hypotension, severe post-spinal anesthesia hypotension (defined as a decline in SBP to $>20\%$ and 40% of baseline, respectively; managed with a 6- μg IV norepinephrine bolus), bradycardia (defined as a HR < 60 beats/min, managed with a 0.5 mg IV atropine bolus), nausea or vomiting, and reactive hypertension (defined as an increase in SBP $> 20\%$ of baseline; managed by discontinuing norepinephrine infusion until recovery), Apgar scores (1 and 5 min; with a ratio of <7), and umbilical artery blood gas (pH, PCO_2 , PO_2 , and base excess [BE]).

Statistical Analysis

The statistical methodology Review suggests that, due to the non-independence and uncertain arrangement of response sequence data, it is advisable to include 20–40 patients in most trials using the up-and-down sequential allocation methodology.¹³ Moreover, to enhance the overall performance in the up-and-down sequential allocation methodology, it is recommended to adjust the step size and boundaries while ensuring a sample size of 30–60 and avoiding a sample size less than 20.¹⁴ Thus, the determination of 30 patients for each of the three groups was based on a stable estimation of ED 90 in our study.

The data analysis was conducted using the SPSS software, version 23.0 for Microsoft Windows (SPSS, Inc., Chicago, IL, USA). The Shapiro–Wilk test was used to assess the normality of continuous data, which were presented as either mean \pm SD and analyzed using an ANOVA test with a post hoc Bonferroni test for multiple comparisons or median (interquartile range, IQR) and analyzed using Kruskal–Wallis test with a post hoc Dunn test for multiple comparisons as appropriate. Chi-squared tests were used for both overall and pairwise comparisons, and the results were presented as numbers (%). The ED90 of prophylactic norepinephrine infusion was calculated using the isotonic regression model. A P value <0.05 was considered to indicate statistical significance.

Results

Ninety patients were randomly assigned to three groups of 30 each and subsequently included in the final analysis. The CONSORT flow diagram shows patient recruitment (Figure 1). Patient demographics and surgical characteristics were comparable among the groups (Table 1).

The sequences of responses and response rates to varying rates of norepinephrine infusion among the groups are shown in Figure 2A–C and Table 2. The estimated effective dose of norepinephrine infusion, at which 90% (ED 90) of patients responded, was found to be 0.084 $\mu\text{g}/\text{kg}/\text{min}$ (95% CI, 0.070 to 0.86), 0.074 $\mu\text{g}/\text{kg}/\text{min}$ (95% CI, 0.059 to 0.077), and 0.063 $\mu\text{g}/\text{kg}/\text{min}$ (95% CI, 0.053 to 0.064) in the three groups, respectively.

The observed outcomes, including maternal adverse events and neonatal Apgar scores and umbilical artery blood gas values, were comparable among the three groups (Table 3).

Discussion

In our study, we observed that crystalloid coload (5 mL/kg and 10 mL/kg) combined with prophylactic norepinephrine infusion were efficacious in preventing post-spinal anesthesia hypotension during cesarean section. Administration of




Figure 1 The CONSORT flow diagram.

both 5mL/kg and 10mL/kg of crystalloid coload reduced ED90 of prophylactic norepinephrine infusion when compared to no crystalloid coload.

Qian et al¹¹ conducted an up-and-down sequential allocation method and probit regression analysis to determine an ED90 of 0.080 (95% CI, 0.069–0.120) $\mu\text{g}/\text{kg}/\text{min}$ for preventing post-spinal anesthesia hypotension with a crystalloid coload of 10 mL/kg in combination with prophylactic norepinephrine infusion. Our findings suggest that the ED90 was comparatively lower, which may be attributed to a lesser block height (average T6 vs T4) during spinal anesthesia. Despite administering a higher dose of bupivacaine (12.5 mg) compared to Qian et al (10 mg), we intentionally and habitually maintained a lower block height in order to prevent significant changes in maternal hemodynamics. A higher block height leads to a more extensive sympathetic blockade, which increases the likelihood of inducing maternal

Table 1 Patient Demographics, Baseline Values, Anesthetic and Surgical Characteristics

| | 0 mL/kg Group (n=30) | 5 mL/kg Group (n=30) | 10 mL/kg Group (n=30) | P value |
|---|----------------------|----------------------|-----------------------|---------|
| Age (yr), | 30.6 (4.2) | 32.6 (4.6) | 30.5 (4.6) | 0.127 |
| BMI (kg/m) | 29.7 (3.9) | 28.1 (3.1) | 28.2 (2.8) | 0.113 |
| Baseline values | | | | |
| Systolic blood pressure (mmHg) | 122.1 (10.8) | 123.1 (10.7) | 122.0 (10.9) | 0.912 |
| Heart rate (beats/min) | 89.8 (15.3) | 95.4 (15.9) | 96.8 (13.1) | 0.162 |
| Block height (T) | T5 (T4 to T6) | T6 (T5 to T6) | T6 (T5 to T6) | 0.260 |
| Consumption of norepinephrine (μg) | 70.4 (32.6) | 62.2 (19.0) | 59.0 (17.0) | 0.012 |
| Volume of coload (mL) | 0.0 (0.0) | 368.8 (43.9) | 754.7 (73.9) | < 0.001 |
| Anesthesia - delivery interval (min) | 14.4 (2.3) | 13.9 (2.8) | 14.5 (2.2) | 0.546 |
| Skin incision - delivery interval (min) | 3.1 (1.1) | 2.6 (1.0) | 2.8 (1.2) | 0.185 |
| Length of postoperative hospital stay (days) | 3.6 (0.9) | 3.3 (0.5) | 3.4 (0.7) | 0.148 |

Note: Data are presented as mean (SD) and median (IQR).

Abbreviation: BMI, body mass index.




Figure 2 The sequence of effective or ineffective responses to varying rates of norepinephrine infusion in the 0mL/kg (A), 5mL/kg (B), and 10mL/kg (C) groups, respectively. NE, norepinephrine.

hypotension and poses challenges for correction. Xu et al¹² conducted an investigation into the ED95 of varying doses of prophylactic norepinephrine infusion (0, 0.025, 0.05, 0.075 and 0.1 µg/kg/min) combined with a crystalloid coload of 10 mL/kg; their findings revealed that the ED95 was estimated at 0.097 (95% CI, 0.072 to 0.157) µg/kg/min though probit regression analysis. It should be noted that the higher ED95 may be attributed to different research and statistical methodologies, which can impact the final results. The probit regression method is well-suited for conducting

Table 2 Response Rates to Varying Rates of Norepinephrine Infusion

| Assigned Dose of Noradrenaline (µg/kg/min) | 0 mL/kg Group (n=30) | | | 5 mL/kg Group (n=30) | | | 10 mL/kg Group (n=30) | | |
|--|----------------------|--------------------|-------------------|----------------------|--------------------|-------------------|-----------------------|--------------------|-------------------|
| | Number of Successes | Number of Patients | Response Rate (%) | Number of Successes | Number of Patients | Response Rate (%) | Number of Successes | Number of Patients | Response Rate (%) |
| 0.025 | 0 | 1 | 0.0% | 0 | 1 | 0.0% | 1 | 2 | 50.0% |
| 0.030 | 0 | 1 | 0.0% | 0 | 1 | 0.0% | 0 | 1 | 0.0% |
| 0.035 | 1 | 2 | 50.0% | 1 | 2 | 50.0% | 1 | 2 | 50.0% |
| 0.040 | 0 | 1 | 0.0% | 1 | 2 | 50.0% | 1 | 2 | 50.0% |
| 0.045 | 1 | 2 | 50.0% | 1 | 2 | 50.0% | 1 | 2 | 50.0% |
| 0.050 | 1 | 2 | 50.0% | 2 | 3 | 66.7% | 2 | 4 | 50.0% |
| 0.055 | 0 | 1 | 0.0% | 2 | 3 | 66.7% | 5 | 6 | 83.3% |
| 0.060 | 1 | 2 | 50.0% | 2 | 3 | 66.7% | 3 | 5 | 60.0% |
| 0.065 | 2 | 3 | 66.7% | 2 | 3 | 66.7% | 6 | 6 | 100.0% |
| 0.070 | 1 | 2 | 50.0% | 3 | 5 | 60.0% | – | – | % |
| 0.075 | 2 | 3 | 66.7% | 5 | 5 | 100.0% | – | – | % |
| 0.080 | 4 | 6 | 66.7% | – | – | % | – | – | % |
| 0.085 | 4 | 4 | 100.0% | – | – | % | – | – | % |

Table 3 Maternal Adverse Events and Neonatal Outcomes

| | 0 mL/kg Group (n=30) | 5 mL/kg Group (n=30) | 10 mL/kg Group (n=30) | P value |
|---|----------------------|----------------------|-----------------------|---------|
| Postspinal anesthesia hypotension, n (%) | 12 (40.0) | 11 (36.7) | 10 (33.3) | 0.866 |
| Severe postspinal anesthesia hypotension, n (%) | 1 (3.3) | 1(3.3) | 1 (3.3) | 1.000 |
| Bradycardia, n (%) | 3 (10.0) | 2 (6.7) | 2 (6.7) | 0.856 |
| Nausea or vomiting, n (%) | 5 (16.7) | 3 (10.0) | 3 (10.0) | 0.661 |
| Intraoperative hypertension, n (%) | 2 (6.7) | 1 (3.3) | 1 (3.3) | 0.770 |
| Birth weight (g) | 3082 (553) | 3175 (439) | 3209 (626) | 0.651 |
| Umbilical arterial pH | 7.35 (0.04) | 7.35 (0.04) | 7.34 (0.04) | 0.741 |
| Umbilical arterial PCO ₂ (mmHg) | 42.4 (6.6) | 40.6 (5.2) | 41.9 (5.8) | 0.460 |
| Umbilical arterial PO ₂ (mmHg) | 23.0 (6.8) | 24.9 (6.4) | 23.6 (5.5) | 0.498 |
| Umbilical arterial BE (mmol/L) | –3.0 (1.4) | –3.0 (1.6) | –2.8 (1.5) | 0.794 |
| Apgar score at 1 min, n (%) | 9 (8 to 9) | 9 (9 to 9) | 9 (9 to 9) | 0.486 |
| Apgar score < 7 at 1 min, n (%) | 0 (0) | 0 (0) | 0 (0) | – |
| Apgar score at 5 min, n (%) | 10 (9 to 10) | 10 (10 to 10) | 10 (10 to 10) | 0.442 |
| Apgar score <7 at 5 min, n (%) | 0 (0) | 0 (0) | 0 (0) | – |

Note: Data are presented as number (%), mean (SD) or median (IQR).
Abbreviation: BE, base excess.

probabilistic analysis on primary endpoint, such as the incidence of post-spinal anesthesia hypotension. However, the assessment of ED90 using isotonic regression analysis, which provides more accurate ED90 and a smaller 95% CI, is more appropriate for the up-and-down sequence allocation methodology employed in our study, despite logistic or probit regression methods being more commonly utilized prior to the introduction of isotonic regression analysis.¹⁴

Ngan Kee et al¹⁵ compared the efficacy of a minimal crystalloid infusion rate for maintaining vein patency with that of rapid crystalloid coload (up to 2000 mL until uterine incision) combined with prophylactic phenylephrine infusion (100 µg/min). They found that the latter approach reduced the incidence of post-spinal anesthesia hypotension (1.9% vs 28.3%; $P = 0.001$), while neonatal outcomes, including pH and BE, were similar in both groups despite different crystalloid infusion rates. Buthelezi et al¹⁶ added the initial 1000 mL crystalloid with 500 µg of phenylephrine (20–50 µg/min) as a coload (approximately 10mL/kg in their report) in resource-limited settings, resulting in a reduction in the incidence of post-spinal anesthesia hypotension (37% vs 51%; $P = 0.011$) and lower lowest SBP (94.6 vs 89.0 mmHg; $P < 0.01$) compared to no prophylactic phenylephrine infusion. In addition, Ngan Kee et al¹⁷ employed a maximal 2000 mL crystalloid coload in combination with prophylactic norepinephrine infusion (5µg/mL; 2.5 µg/min). They observed a reduction in patients with one or more episodes of post-spinal anesthesia hypotension among patients who received this combination therapy compared to those who only received crystalloid coload (17% vs 66%; $P < 0.001$), as well as more stable hemodynamics (MDPE: -2.99 vs -11.15; $P < 0.001$; MDAPE: 4.97 vs 11.33; $P < 0.001$). In our study, no significant difference in the incidence of post-spinal anesthesia hypotension was observed when crystalloid coload was not administered for preventing post-spinal anesthesia hypotension as compared to the administration of either 5 mL/kg or 10 mL/kg of crystalloid coload in combination with a prophylactic norepinephrine infusion. However, a crystalloid coload of either 5 mL/kg or 10 mL/kg resulted in a reduction of ED90 of the prophylactic norepinephrine infusion in comparison to no crystalloid coload. This also helps clarify the initial dose of prophylactic norepinephrine infusion with different crystalloid coload doses. For instance, when administering higher doses of crystalloid coload, it is advisable to avoid an elevated initial infusion dose of prophylactic norepinephrine in order to minimize maternal exposure to exogenous catecholamines. Once again, it is recommended that vasopressors remain the primary strategy for managing post-spinal anesthesia hypotension during cesarean section, while fluid loading may further enhance hemodynamic stability when prophylactic vasopressors are administered.

Fluid loading is a highly effective supplement strategy that plays a crucial role in managing post-spinal anesthesia hypotension. This technique involves the administration of fluids to increase venous return, which helps counteract hypovolemia.¹⁸ By replenishing the body's fluid levels, fluid loading can help stabilize blood pressure and prevent complications associated with spinal anesthesia. Both coload and preload are commonly used methods for fluid loading in clinical practice. The preload strategy alone has not proved effective for preventing post-spinal anesthesia hypotension during cesarean section.¹⁹ A large volume of intravenously administered preload, especially crystalloid, will rapidly redistribute into the extracellular space thus decreasing the colloid oncotic pressure.²⁰ Additionally, with crystalloid preloading, atrial natriuretic peptide release is stimulated by atrial stretching resulting in diuresis and peripheral vasodilation, thus reducing intravascular fluid volume and pressure.²¹ In our study, a crystalloid preload of 5mL/kg was administered to avoid preoperative dehydration and compensate for apparent body fluid loss when coload was not administered. Coload is superior to preload and its superiority lies in the fact that the increased fluid volume administered coincides with peak arterial dilation, so excessive fluid redistribution is avoided because hydrostatic pressure is decreased with spinal-induced vasodilation. It should be noted that a large volume of coload may increase this associated risk. The superiority of coload, however, lies in its ability to avoid excessive fluid redistribution resulting from the increased fluid volume that coincides with peak arterial dilation.²² Crystalloid is an economical option with minimal adverse effects. When administered intravenously, it serves as a potent volume expander in clinical settings. However, due to its small molecules, it remains in the intravascular space for a shorter period of time and may readily diffuse into the extravascular space, potentially leading to edema.²³

Referring to both practice guidelines for obstetric anesthesia and an international consensus statement, the administration of α -receptor agonists is recommended as a primary strategy of managing post-spinal anesthesia hypotension during cesarean section.^{7,24} Ephedrine, with its ability to effortlessly cross the placental barrier, is a contributing factor to neonatal acidosis caused by direct fetal β -receptor agonists.²⁵ It has been replaced with norepinephrine and

phenylephrine. Because it is a potent α -adrenergic agonist with weak β -adrenergic receptor agonist activity, norepinephrine may be more suitable for maintaining hemodynamic stability with minimal cardiac depression and lower incidence of bradycardia than phenylephrine.²⁶ Ngan Kee et al²⁷ conducted a randomized non-inferiority study and found that the use of norepinephrine for blood pressure maintenance did not exhibit any deleterious impact on the pH of the umbilical artery. Furthermore, it was determined to be non-inferior to phenylephrine in terms of efficacy. Owing to its rapid onset and short duration of action, as well as its restricted ability to cross the placental barrier, norepinephrine may facilitate maternal hypotension correction and maintain optimal fetal acid-base status.²⁶ In accordance to the aforementioned results, our study, using a combination of prophylactic norepinephrine infusion and crystalloid coload, demonstrated that active management of maternal hypotension and hemodynamic stability effectively maintained neonatal outcomes within normal range, as evidenced by umbilical artery blood gas values and Apgar scores, while minimizing maternal adverse effects such as nausea and vomiting.

This study is subject to certain limitations. A higher volume of coload, such as 15 mL/kg or 20 mL/kg, was not explored in our study to further determine the ED90 for preventing post-spinal anesthesia hypotension, so as to preclude an increased risk of tissue and pulmonary edema. Loubert et al⁸ have indicated that administering crystalloid fluid volumes ranging from 500 to 1000 mL can effectively achieve optimal hemodynamic status, and increasing fluid volumes does not offer any additional benefits. A subsequent meta-analysis has similar results.¹⁸ However, the optimal volume of coload remains to be explored. Uteroplacental blood perfusion primarily relies on maternal cardiac output, with blood pressure serving as a surrogate marker for cardiac output. Therefore, hemodynamic indices such as cardiac output, cardiac index, and stroke volume variation may be more desirable for guiding fluid loading.

Conclusion

A crystalloid coload of 5 mL/kg or 10 mL/kg was found to decrease the ED 90 of prophylactic norepinephrine infusion for preventing post-spinal anesthesia hypotension during cesarean section by approximately 11.9% and 25.0%, respectively, compared to no crystalloid coload.

Data Sharing Statement

The data that support the study findings are available from the corresponding author upon reasonable request.

Funding

This work was supported by the Ningxia Natural Science Foundation (No. 2022AAC03591), the Ningxia Health System Fund for Scientific Research (No. 2022-NWKY-056).

Disclosure

The authors report no conflicts of interest in this work.

References

- Weiniger CF, Heesen M, Knigin D, et al. Association between hyperbaric bupivacaine dose and maternal hypotension: retrospective database study of 8226 women undergoing cesarean delivery under spinal anesthesia. *Anesth Analg.* 2021;133:967–975. doi:10.1213/ANE.0000000000005518
- Nagarajan S, Chan JJI, Tan CW, et al. An advanced double intravenous vasopressor automated system to treat hypotension during spinal anaesthesia for caesarean section: a pilot study. *Eur J Anaesthesiol.* 2022;39:42–49. doi:10.1097/EJA.0000000000001496
- Weiniger CF, Gerard W. Ostheimer Lecture: what's New in Obstetric Anesthesia 2018. *Anesth Analg.* 2020;131:307–316. doi:10.1213/ANE.0000000000004714
- Du EW, Tan HS, Tan CW, Sultana R, Sng BL. Heart rate variability and haemodynamic factors associated with hypotension during spinal anaesthesia for caesarean delivery: a case-control study. *Eur J Anaesthesiol.* 2022;39:219–226. doi:10.1097/EJA.0000000000001551
- Belin O, Casteres C, Alouini S, Le Pape M, Dupont A, Boulain T. Manually controlled, continuous infusion of phenylephrine or norepinephrine for maintenance of blood pressure and cardiac output during spinal anesthesia for cesarean delivery: a double-blinded randomized study. *Anesth Analg.* 2023;136:540–550. doi:10.1213/ANE.0000000000006244
- Singh PM, Singh NP, Reschke M, Ngan Kee WD, Palanisamy A, Monks DT. Vasopressor drugs for the prevention and treatment of hypotension during neuraxial anaesthesia for Caesarean delivery: a Bayesian network meta-analysis of fetal and maternal outcomes. *Br J Anaesth.* 2020;124:e95–e107. doi:10.1016/j.bja.2019.09.045
- Kinsella SM, Carvalho B, Dyer RA, et al. International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia. *Anaesthesia.* 2018;73:71–92. doi:10.1111/anae.14080

8. Loubert C. Fluid and vasopressor management for cesarean delivery under spinal anesthesia: continuing professional development. *Can J Anaesth.* 2012;59:604–619. doi:10.1007/s12630-012-9705-9
9. Park GE, Hauch MA, Curlin F, Datta S, Bader AM. The effects of varying volumes of crystalloid administration before cesarean delivery on maternal hemodynamics and colloid osmotic pressure. *Anesth Analg.* 1996;83:299–303. doi:10.1097/00000539-199608000-00017
10. Kaufner L, Karekla A, Henkelmann A, et al. Crystalloid coload vs. colloid coload in elective Caesarean section: postspinal hypotension and vasopressor consumption, a prospective, observational clinical trial. *J Anesth.* 2019;33:40–49. doi:10.1007/s00540-018-2581-x
11. Qian J, Zhao YP, Deng JL, et al. Determination of the relative potency of norepinephrine and phenylephrine given as infusions for preventing hypotension during combined spinal-epidural anesthesia for cesarean delivery: a randomized up-and-down sequential allocation study. *Front Pharmacol.* 2022;13:942005. doi:10.3389/fphar.2022.942005
12. Xu WP, Drzymalski DM, Ai L, et al. The ED50 and ED95 of prophylactic norepinephrine for preventing post-spinal hypotension during cesarean delivery under combined spinal-epidural anesthesia: a prospective dose-finding study. *Front Pharmacol.* 2021;12:691809. doi:10.3389/fphar.2021.691809
13. Pace NL, Stylianou MP. Advances in and limitations of up-and-down methodology: a précis of clinical use, study design, and dose estimation in anesthesia research. *Anesthesiology.* 2007;107:144–152. doi:10.1097/01.anes.0000267514.42592.2a
14. Oron AP, Souter MJ, Flournoy N. Understanding research methods: up-and-down designs for dose-finding. *Anesthesiology.* 2022;137(2):137–150. doi:10.1097/ALN.0000000000004282
15. Ngan Kee WD, Khaw KS, Ng FF, et al. Prevention of hypotension during spinal anesthesia for cesarean delivery: an effective technique using combination phenylephrine infusion and crystalloid cohydration. *Anesthesiology.* 2005;103:744–750. doi:10.1097/00000542-200510000-00012
16. Buthelezi AS, Bishop DG, Rodseth RN, Dyer RA. Prophylactic phenylephrine and fluid co-administration to reduce spinal hypotension during elective caesarean section in a resource-limited setting: a prospective alternating intervention study. *Anaesthesia.* 2020;75:487–492. doi:10.1111/anae.14950
17. Ngan Kee WD, Lee SWY, Ng FF, Khaw KS. Prophylactic norepinephrine infusion for preventing hypotension during spinal anesthesia for cesarean delivery. *Anesth Analg.* 2018;126:1989–1994. doi:10.1213/ANE.0000000000002243
18. Rijs K, Mercier FJ, Lucas DN, Rossaint R, Klimek M, Heesen M. Fluid loading therapy to prevent spinal hypotension in women undergoing elective caesarean section: network meta-analysis, trial sequential analysis and meta-regression. *Eur J Anaesthesiol.* 2020;37:1126–1142. doi:10.1097/EJA.0000000000001371
19. Banerjee A, Stocche RM, Angle P, Halpern SH. Preload or coload for spinal anesthesia for elective Cesarean delivery: a meta-analysis. *Can J Anaesth.* 2010;57:24–31. doi:10.1007/s12630-009-9206-7
20. Bajwa SJ, Kulshrestha A, Jindal R. Co-loading or pre-loading for prevention of hypotension after spinal anaesthesia! A therapeutic dilemma. *Anesth Essays Res.* 2013;7:155–159. doi:10.4103/0259-1162.118943
21. Massoth C, Töpel L, Wenk M. Hypotension after spinal anesthesia for cesarean section: how to approach the iatrogenic sympathectomy. *Curr Opin Anaesthesiol.* 2020;33:291–298. doi:10.1097/ACO.0000000000000848
22. Lee JE, George RB, Habib AS. Spinal-induced hypotension: incidence, mechanisms, prophylaxis, and management: summarizing 20 years of research. *Best Pract Res Clin Anaesthesiol.* 2017;31:57–68. doi:10.1016/j.bpa.2017.01.001
23. Theodoraki K, Hadzilia S, Valsamidis D, Kalopita K, Stamatakis E. Colloid preload versus crystalloid co-load in the setting of norepinephrine infusion during cesarean section: time and type of administered fluids do not matter. *J Clin Med.* 2023;12:1333. doi:10.3390/jcm12041333
24. Apfelbaum JL. Practice Guidelines for Obstetric Anesthesia: an updated report by the American Society of Anesthesiologists Task Force on obstetric anesthesia and the Society for Obstetric Anesthesia and Perinatology. *Anesthesiology.* 2016;124:270–300. doi:10.1097/ALN.0000000000000935
25. Higgins N, Fitzgerald PC, van Dyk D, et al. The effect of prophylactic phenylephrine and ephedrine infusions on umbilical artery blood pH in women with preeclampsia undergoing cesarean delivery with spinal anesthesia: a randomized, double-blind trial. *Anesth Analg.* 2018;126:1999–2006. doi:10.1213/ANE.0000000000002524
26. Mohta M, Garg A, Chilkoti GT, Malhotra RK. A randomised controlled trial of phenylephrine and noradrenaline boluses for treatment of postspinal hypotension during elective caesarean section. *Anaesthesia.* 2019;74:850–855. doi:10.1111/anae.14675
27. Ngan Kee WD, Lee SWY, Ng FF, Lee A. Norepinephrine or phenylephrine during spinal anaesthesia for Caesarean delivery: a randomised double-blind pragmatic non-inferiority study of neonatal outcome. *Br J Anaesth.* 2020;125:588–595. doi:10.1016/j.bja.2020.05.057

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>